Comprehensive Pharmacogenomic Study Reveals an Important Role of UGT1A3 in Montelukast Pharmacokinetics

Clinical Pharmacology and Therapeutics

Volumn 104, Issue 1, 2018, Pages 158-168

  Hirvensalo, Päivi ^a   Tornio, Aleksi ^a   Neuvonen, Mikko ^a   Tapaninen, Tuija ^a   Paile Hyvärinen, Maria ^a   Kärjä, Vesa ^b   Männistö, Ville T ^c   Pihlajamäki, Jussi ^b,c   Backman, Janne T ^a   Niemi, Mikko ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C8; GLUCURONOSYLTRANSFERASE 1A3; MONTELUKAST; ABCC9 PROTEIN, HUMAN; ACETIC ACID; CYP2C8 PROTEIN, HUMAN; CYTOCHROME P450 1A2 INDUCER; GLUCURONOSYLTRANSFERASE; QUINOLINE DERIVATIVE; SLCO1B1 PROTEIN, HUMAN; SULFONYLUREA RECEPTOR; UDP-GLUCURONOSYLTRANSFERASE, UGT1A3;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; ELIMINATION HALF-LIFE; FEMALE; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIATION; HAPLOTYPE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; LIVER; MALE; MAXIMUM CONCENTRATION; NORMAL HUMAN; PHARMACOGENOMICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; GENETICS; METABOLISM; PHARMACOGENETIC TESTING; YOUNG ADULT;

ACETATES; ADULT; AREA UNDER CURVE; CYTOCHROME P-450 CYP1A2 INDUCERS; CYTOCHROME P-450 CYP2C8; FEMALE; GLUCURONOSYLTRANSFERASE; HUMANS; IN VITRO TECHNIQUES; LIVER-SPECIFIC ORGANIC ANION TRANSPORTER 1; MALE; PHARMACOGENOMIC TESTING; POLYMORPHISM, SINGLE NUCLEOTIDE; QUINOLINES; SULFONYLUREA RECEPTORS; YOUNG ADULT;

EID: 85048561913     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.891     Document Type: Article

References (50)

1. Fanta, C.H. Asthma. N. Engl. J. Med. 360, 1002–1014 (2009).
2. Balani, S.K. et al. Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile. Drug Metab. Dispos. 25, 1282–1287 (1997).
3. Karonen, T., Filppula, A., Laitila, J., Niemi, M., Neuvonen, P.J. & Backman, J.T. Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast. Clin. Pharmacol. Ther. 88, 223–230 (2010).
4. Filppula, A.M., Laitila, J., Neuvonen, P.J. & Backman, J.T. Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. Drug Metab. Dispos. 5, 904–911 (2011).
5. Chiba, M., Xu, X., Nishime, J.A., Balani, S.K. & Lin, J.H. Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans. Drug Metab. Dispos. 25, 1022–1031 (1997).
6. Karonen, T., Neuvonen, P.J. & Backman, J.T. CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast. Br. J. Clin. Pharmacol. 73, 257–267 (2012).
7. de Oliveira Cardoso, J., Oliveira, R.V., Lu, J.B. & Desta, Z. In vitro metabolism of montelukast by cytochrome P450s and UDP-glucuronosyltransferases. Drug Metab. Dispos. 43, 1905–1916 (2015).
8. Mougey, E.B., Feng, H., Castro, M., Irvin, C.G. & Lima, J.J. Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet. Genomics 19, 129–138 (2009).
9. Chu, X., Philip, G. & Evers, R. Comments on Mougey et al. (2009): Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet. Genomics 19: 129–138. Pharmacogenet. Genomics. 22, 319–322 (2012).
10. Varma, M.V. et al. Transporter-mediated hepatic uptake plays an important role in the pharmacokinetics and drug-drug interactions of montelukast. Clin. Pharmacol. Ther. 101, 406–415 (2017).
11. Niemi, M., Pasanen, M.K. & Neuvonen, P.J. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol. Rev. 63, 157–181 (2011).
12. Kuehl, G.E., Lampe, J.W., Potter, J.D. & Bigler, J. Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab. Dispos. 33, 1027–1035 (2005).
13. Guillemette, C., Lévesque, É. & Rouleau, M. Pharmacogenomics of human uridine diphospho-glucuronosyltransferases and clinical implications. Clin. Pharmacol. Ther. 96, 324–339 (2014).
14. Riedmaier, S. et al. UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin. Pharmacol. Ther. 87, 65–73 (2010).
15. Ieiri, I. et al. Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose. Pharmacogenet. Genomics 21, 495–505 (2011).
16. Lin, M. et al. Effects of UDP-glucuronosyltransferase (UGT) polymorphisms on the pharmacokinetics of febuxostat in healthy Chinese volunteers. Drug Metab. Pharmacokinet. 32, 77–84 (2017).
17. Erichsen, T.J., Aehlen, A., Ehmer, U., Kalthoff, S., Manns, M.P. & Strassburg, C.P. Regulation of the human bile acid UDP-glucuronosyltransferase 1A3 by the farnesoid X receptor and bile acids. J. Hepatol. 52, 570–578 (2010).
18. Hu, D.G., Meech, R., McKinnon, R.A. & Mackenzie, P.I. Transcriptional regulation of human UDP-glucuronosyltransferase genes. Drug Metab. Rev. 46, 421–458 (2014).
19. Iwai, M., Maruo, Y., Ito, M., Yamamoto, K., Sato, H. & Takeuchi, Y. Six novel UDP-glucuronosyltransferase (UGT1A3) polymorphisms with varying activity. J. Hum. Genet. 49, 123–128 (2004).
20. Chen, Y., Chen, S., Li, X., Wang, X. & Zeng, S. Genetic variants of human UGT1A3: functional characterization and frequency distribution in a Chinese Han population. Drug Metab. Dispos. 34, 1462–1467 (2006).
21. Caillier, B. et al. A pharmacogenomics study of the human estrogen glucuronosyltransferase UGT1A3. Pharmacogenet. Genomics 17, 481–495 (2007).
22. Niemi, M. et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 7, 429–440 (2004).
23. Pasanen, M.K., Neuvonen, M., Neuvonen, P.J. & Niemi, M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genomics 16, 873–879 (2006).
24. Pasanen, M.K., Fredrikson, H., Neuvonen, P.J. & Niemi, M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther. 6, 726–733 (2007).
25. Nies, A.T. et al. Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. Genome Med. 5, 1–11 (2013).
26. Bryan, J. et al. ABCC8 and ABCC9: ABC transporters that regulate K+ channels. Pflugers Arch. 5, 703–718 (2007).
27. Kamide, K. et al. Genome-wide response to antihypertensive medication using home blood pressure measurements: a pilot study nested within the HOMED-BP study. Pharmacogenomics 14, 1709–1721 (2013).
28. Grady, B.J. et al. Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-naïve ACTG clinical trials participants. Pac. Symp. Biocomput. 253–264 (2011).
29. Niemi, M., Leathart, J.B., Neuvonen, M., Backman, J.T., Daly, A.K. & Neuvonen, P.J. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin. Pharmacol. Ther. 74, 380–387 (2003).
30. Kirchheiner, J. et al. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clin. Pharmacol. Ther. 80, 657–667 (2006).
31. Tornio, A., Niemi, M., Neuvonen, P.J. & Backman, J.T. Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metab. Dispos. 36, 73–80 (2008).
32. Aquilante, C.L., Niemi, M., Gong, L., Altman, R.B. & Klein, T.E. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8. Pharmacogenet. Genomics 12, 721–728 (2013).
33. Tornio, A. et al. Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions. Clin. Pharmacol. Ther. 96, 498–507 (2014).
34. Barratt, D.T. et al. CYP2C8 genotype significantly alters imatinib metabolism in chronic myeloid leukaemia patients. Clin. Pharmacokinet. 56, 977–985 (2017).
35. Backman, J.T., Filppula, A.M., Niemi, M. & Neuvonen, P.J. Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol. Rev. 68:168–241 (2016).
36. Hon, K.L., Leung, T.F. & Leung, A.K. Clinical effectiveness and safety of montelukast in asthma. What are the conclusions from clinical trials and meta-analyses? Drug Des. Dev. Ther. 26, 839–850 (2014).
37. Thompson, M.D. et al. Cysteinyl leukotrienes pathway genes, atopic asthma and drug response: from population isolates to large genome-wide association studies. Front. Pharmacol. 7:299 eCollection (2016).
38. Zhao, J.J. et al. Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers. Biopharm. Drug Dispos. 18, 769–777 (1997).
39. Noonan, M.J. et al. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group. Eur. Respir. J. 11, 1232–1239 (1998).
40. Männistö, V.T. et al. Lipoprotein subclass metabolism in nonalcoholic steatohepatitis. J. Lipid Res. 55, 2676–2684 (2014).
41. Nilsson, E. et al. Epigenetic alterations in human liver from subjects with type 2 diabetes in parallel with reduced folate levels. J. Clin. Endocrinol. Metab. 100, E1491–E1501 (2015).
42. Pihlajamäki, J. et al. Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans. J. Hepatol. 56, 663–670 (2012).
43. Sulonen, A.M. et al. Comparison of solution-based exome capture methods for next generation sequencing. Genome Biol. 12, R94 (2011).
44. Clinical Pharmacology & Therapeutics Editorial Team. Statistical guide for Clinical Pharmacology & Therapeutics. Clin. Pharmacol. Ther. 88, 150–152 (2010).
45. Hallynck, T.H., Soep, H.H., Thomis, J.A., Boelaert, J., Daneels, R. & Dettli, L. Should clearance be normalised to body surface or to lean body mass? Br. J. Clin. Pharmacol. 11, 523–526 (1981).
46. Haycock, G.B., Schwartz, G.J. & Wisotsky, D.H. Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. J. Pediatr. 93, 62–66 (1978).
47. Gabriel, S.B. et al. The structure of haplotype blocks in the human genome. Science 296, 2225–2229 (2002).
48. Wall, J.D. & Pritchard, J.K. Assessing the performance of the haplotype block model of linkage disequilibrium. Am. J. Hum. Genet. 73, 502–515 (2003).
49. Stephens, M., Smith, N.J. & Donnelly, P. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68, 978–989 (2001).
50. Stephens, M. & Donnelly, P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am. J. Hum. Genet. 73, 1162–1169 (2003).